Epo/EpoR signaling in osteoprogenitor cells is essential for bone homeostasis and Epo-induced bone loss

Abstract

High erythropoietin (Epo) levels are detrimental to bone health in adult organisms. Adult mice receiving high doses of Epo lose bone mass due to suppressed bone formation and increased bone resorption. In humans, high serum Epo levels are linked to fractures in elderly men. Our earlier studies indicated that Epo modulates osteoblast activity; however, direct evidence that Epo acts via its receptor (EpoR) on osteoblasts in vivo is still missing. Here, we created mice lacking EpoR in osteoprogenitor cells to specifically address this gap. Deletion of EpoR in osteoprogenitors (EpoR:Osx-cre, cKO) starting at 5 weeks of age did not alter red blood cell parameters but increased vertebral bone volume by 25% in 12-week-old female mice. This was associated with low bone turnover. Histological (osteoblast number, bone formation rate) and serum (P1NP, osteocalcin) bone formation parameters were all reduced, as were the number of osteoclasts and TRAP serum level. Differentiation of osteoblast precursors isolated from cKO versus control mice resulted in lower expression of osteoblast marker genes including Runx2, Alp, and Col1a1 on day 21, whereas the mineralization capacity was similar. Moreover, the RANKL/OPG ratio, which determines the osteoclast-supporting potential of osteoblasts, was substantially decreased by 50%. Similarly, coculturing cKO osteoblasts with control or cKO osteoclast precursors produced significantly fewer osteoclasts than coculture with control osteoblasts. Finally, exposing female mice to Epo pumps (10 U·d⁻¹) for 4 weeks resulted in trabecular bone loss (−25%) and increased osteoclast numbers (1.7-fold) in control mice only, not in cKO mice. Our data show that EpoR in osteoprogenitors is essential in regulating osteoblast function and osteoblast-mediated osteoclastogenesis via the RANKL/OPG axis. Thus, osteogenic Epo/EpoR signaling controls bone mass maintenance and contributes to Epo-induced bone loss.

References

[1] Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N. Engl. J. Med., 1987, 316: 73-78

[2] Skali H et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with DarbEpoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation, 2011, 124: 2903-2908

[3] Verhoef GE et al. Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment. Ann. Hematol., 1992, 64: 16-21

[4] Bohlius J et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. J. Clin. Oncol., 2019, 37: 1336-1351

[5] D’Andrea AD, Lodish HF, Wong GG. Expression cloning of the murine erythropoietin receptor. Cell, 1989, 57: 277-285

[6] Constantinescu SN et al. The anemic Friend virus gp55 envelope protein induces erythroid differentiation in fetal liver colony-forming units-erythroid. Blood, 1998, 91: 1163-1172

[7] Juul SE, Yachnis AT, Rojiani AM, Christensen RD. Immunohistochemical localization of erythropoietin and its receptor in the developing human brain. Pediatr. Dev. Pathol., 1999, 2: 148-158

[8] Maiese K, Li F, Chong ZZ. Erythropoietin in the brain: can the promise to protect be fulfilled? Trends Pharm. Sci., 2004, 25: 577-583

[9] Nakano M et al. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ. Res., 2007, 100: 662-669

[10] Suresh, S., Alvarez, J. C., Dey, S., & Noguchi, C. T. Erythropoietin-induced changes in bone and bone marrow in mouse models of diet-induced obesity. Int. J. Mol. Sci. 21, 1657 (2020).

[11] Jia Y, Suzuki N, Yamamoto M, Gassmann M, Noguchi CT. Endogenous erythropoietin signaling facilitates skeletal muscle repair and recovery following pharmacologically induced damage. FASEB J., 2012, 26: 2847-2858

[12] Hiram-Bab S et al. Erythropoietin directly stimulates osteoclast precursors and induces bone loss. FASEB J., 2015, 29: 1890-1900

[13] Kim J et al. Erythropoietin mediated bone formation is regulated by mTOR signaling. J. Cell Biochem., 2012, 113: 220-228

[14] Li C et al. Erythropoietin promotes bone formation through EphrinB2/EphB4 signaling. J. Dent. Res., 2015, 94: 455-463

[15] Rauner M et al. Increased EPO levels are associated with bone loss in mice lacking PHD2 in EPO-producing cells. J. Bone Min. Res., 2016, 31: 1877-1887

[16] Shiozawa Y et al. Erythropoietin couples hematopoiesis with bone formation. PLoS One, 2010, 5: e10853

[17] Singbrant S et al. Erythropoietin couples erythropoiesis, B-lymphopoiesis, and bone homeostasis within the bone marrow microenvironment. Blood, 2011, 117: 5631-5642

[18] Wan L et al. EPO promotes bone repair through enhanced cartilaginous callus formation and angiogenesis. PLoS One, 2014, 9: e102010

[19] Kolomansky, A., et al. Erythropoietin mediated bone loss in mice is dose-dependent and mostly irreversible. Int. J. Mol. Sci. 21, 3817 (2020).

[20] Kristjansdottir HL et al. High plasma erythropoietin predicts incident fractures in elderly men with normal renal function: the MrOS Sweden Cohort. J. Bone Min. Res., 2020, 35: 298-305

[21] Hiram-Bab S, Neumann D, Gabet Y. Context-dependent skeletal effects of erythropoietin. Vitam. Horm., 2017, 105: 161-179

[22] Bakhshi H et al. Local erythropoietin injection in tibiofibular fracture healing. Trauma Mon., 2013, 17: 386-388

[23] Suresh S, de Castro LF, Dey S, Robey PG, Noguchi CT. Erythropoietin modulates bone marrow stromal cell differentiation. Bone Res., 2019, 7: 21

[24] Suresh, S., Lee, J., Noguchi, C. T. Erythropoietin signaling in osteoblasts is required for normal bone formation and for bone loss during erythropoietin-stimulated erythropoiesis. FASEB J. 34, 11685–11697 (2020).

[25] Chen J et al. Osx-Cre targets multiple cell types besides osteoblast lineage in postnatal mice. PLoS One, 2014, 9: e85161

[26] Flamme I, Ellinghaus P, Urrego D, Kruger T. FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase. PLoS One, 2017, 12: e0186979

[27] Toro L et al. Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury. Kidney Int., 2018, 93: 1131-1141

[28] Deshet-Unger N et al. Erythropoietin receptor in B cells plays a role in bone remodeling in mice. Theranostics, 2020, 10: 8744-8756

[29] Dey, S., et al. Sex-specific brain erythropoietin regulation of mouse metabolism and hypothalamic inflammation. JCI Insight. 5, e134061 (2020).

[30] Zhang Y, Rogers HM, Zhang X, Noguchi CT. Sex difference in mouse metabolic response to erythropoietin. FASEB J., 2017, 31: 2661-2673

[31] Larsson AM et al. Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer. Clin. Cancer Res., 2009, 15: 5552-5559

[32] Rodda SJ, McMahon AP. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development, 2006, 133: 3231-3244

[33] Tsai PT et al. A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J. Neurosci., 2006, 26: 1269-1274

[34] Huang W, Olsen BR. Skeletal defects in Osterix-Cre transgenic mice. Transgenic. Res., 2015, 24: 167-172

[35] Rauner M et al. Transferrin receptor 2 controls bone mass and pathological bone formation via BMP and Wnt signaling. Nat. Metab., 2019, 1: 111-124

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation)

German-Israeli Foundation for Scientific Research and Development (GIF)(#I-1433-203.13_2017)